Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer.

It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.

In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).

[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

[citation needed] This article incorporates public domain material from Dictionary of Cancer Terms.